Echo45 Advisors’s AbbVie ABBV Stock Holding History

Echo45 Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-963	Closed	-$209K	–	79
2026 Q1	$209K	Sell	963 -13	-1%	-$2.88K	0.12%	69
2025 Q4	$223K	Sell	976 -144	-13%	-$32.8K	0.13%	68
2025 Q3	$259K	Buy	+1,120	New	+$228K	0.15%	44
2025 Q2	–	Sell	-1,198	Closed	-$251K	–	53
2025 Q1	$251K	Sell	1,198 -157	-12%	-$30.5K	0.17%	44
2024 Q4	$246K	Buy	+1,355	New	+$249K	0.16%	45

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Echo45 Advisors's ABBV Position: Q2 2026 in Review

Echo45 Advisors sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 963 shares — an estimated $209K sold.

Echo45 Advisors first reported a position in ABBV in Q4 2024 and held it in 5 quarters. The position peaked at $259K in Q3 2025. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Echo45 Advisors reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Echo45 Advisors sold 963 AbbVie shares in Q2 2026, an estimated $209K.
Echo45 Advisors first reported a position in AbbVie in Q4 2024 and held it in 5 quarters.
Echo45 Advisors's AbbVie position peaked at $259K in Q3 2025.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Echo45 Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.